Time from diagnosis to treatment is associated with survival in patients with acute myeloid leukaemia: An analysis of 55 985 patients from the National Cancer Database.
Aseel AlsouqiScott D RothenbergerMichael BoyiadzisKonstantinos LontosPublished in: British journal of haematology (2022)
Acute myeloid leukaemia (AML) is conventionally thought of as a medical emergency. However, several studies on the association of time from diagnosis to treatment with survival did not have concordant results. Here we analyse 55 985 AML patients from the National Cancer Database, and we show that in patients less than 60 years old a five-day delay in chemotherapy initiation leads to worse long-term survival. The difference is small [hazard ratio (HR) 1.05, 95% confidence interval (CI) 1.01-1.09 in multivariate analysis] but statistically significant. This study raises the issue of power to detect small differences in retrospective studies.
Keyphrases
- end stage renal disease
- acute myeloid leukemia
- ejection fraction
- newly diagnosed
- chronic kidney disease
- bone marrow
- prognostic factors
- dendritic cells
- cross sectional
- intensive care unit
- respiratory failure
- replacement therapy
- combination therapy
- adverse drug
- case control
- hepatitis b virus
- data analysis
- allogeneic hematopoietic stem cell transplantation